4. www.venturevaluation.com
Source of new companies
100% 100%
80% 90%
80%
60%
70%
40% 60%
50%
20%
40%
0% 30%
20%
10%
0%
Independent foundation
Spin-off from company
Spin-off from University/Public Institution
Subsidiary
Other Public Private
5. www.venturevaluation.com
Product pipeline
Switzerland 48% 22% 21% 9%
Germany 49% 22% 23% 6%
France 48% 18% 27% 7%
Netherlands 54% 14% 25%7%
UK 51% 16% 25% 8%
Ireland
0 50 100 150 200 250 300 350 400
No. of Products
Preclinical Phase I Phase II Phase III
7. www.venturevaluation.com
Biotechgate
• Subscription based Database with
26‘000 company profiles in over 70 countries
26‘000 products
6‘300 licensing opportunities
1’400 licensing deals
• Global Life Sciences Database to map clusters / countries
• 28 country databases
• Life Sciences statistics
• Membership / Regional Directory
7
9. www.venturevaluation.com
Venture Valuation
Mission Independent assessment and valuation of
technology driven companies / products in
growth industries
Life Sciences Database Biotechgate:
www.biotechgate.com
Offices HQ: Zurich with representative offices in North
America, Europe and Asia (Seoul)
Employees 6 people in Switzerland, 8 representatives, JV in India
Clients Pharma, Biotech and Investors such as Novartis Venture
Fund, GSK, European Investment
Bank, 4SC, Arpida/Evolva, Celtic Pharma
10. www.venturevaluation.com
Thank you for listening!
Slides available on www.venturevaluation.com
Tel.: +41 (43) 321 86 60 Venture Valuation AG
Fax: +41 (43) 321 86 61 Kasernenstrasse 11
www.venturevaluation.com 8004 Zürich
p.frei@venturevaluation.com Switzerland
11. www.venturevaluation.com
Panel Discussion
To be a successful entrepreneur in Switzerland / the Bay
Area – or how to raise more money than you burn?
Participants:
• Simon Meier, Investment Director, Roche Venture Fund
• Simon Nebel, Managing Partner, Aravis
• Christian Zahnd, CEO, Molecular Partners AG
• Panel moderated by Patrik Frei, CEO Venture Valuation
11